Back

The predictive value of baseline troponin measurements in patients treated with immune checkpoint inhibitors

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Emerging insights in cardio-oncology: biomarkers, cardiotoxicity, and protective therapies Cardio-Oncology HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Michal Laufer-Perl

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

6 More presentations in this session

Presentation thumbnail
Sacubitril-valsartan reduced H-FABP, hs-cTnT, hs-CRP and monocyte-to-lymphocyte ratio in anthracycline-treated preclinical models through NLRP3-mTOR-AKT pathways
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Heart failure hospitalization and outcomes in cancer patients undergoing immune checkpoint inhibitor treatment: a systematic review and meta-analysis
Doctor N. Sari (Jakarta, ID)
Abstract Slides Video
Presentation thumbnail
GLP1-RA associated with SGLT2i as new therapy of anthracycline-induced cardiotoxicity under hyperglycemia: biochemical and preclinical evidences
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in cancer patients with diabetes mellitus
Doctor M. Gvili Perelman (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Evaluation of vascular cell adhesion molecule-1 (VCAM-1) level changes in patients with lymphoproliferative diseases during antitumor therapy
Doctor R. Alieva (Tashkent, UZ)
Abstract Slides Video

Access the full session

Session thumbnail
Emerging insights in cardio-oncology: biomarkers, cardiotoxicity, and protective therapies
Video

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
The predictive value of follow-up troponin measurements in patients treated with immune checkpoint inhibitors
thumbnail
Congress Presentation
Cardiovascular adverse events in primary lung cancer patients treated with immune checkpoint inhibitors: a nationwide database study
thumbnail
Congress Presentation
Cardiovascular disease and its association with outcomes in cancer patients treated with immune checkpoint inhibitors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources